A real-world cohort study directly comparing ofatumumab against rituximab in pemphigus vulgaris appears in the October 2026 supplement of the Journal of Investigative Dermatology (Volume 146, Issue 10), adding head-to-head evidence to a field where rituximab has long been the default anti-CD20 choice.

The study comes from a 13-author Chinese research team led by first author Yue Xiao and senior author Deying Kang, with co-investigators from institutions including Mintong Wei, Lewei He, Xiangxuan Piao, Xingli Zhou, Jishu Li, Min Zou, Kun Zhan, Xun Feng and Deying Kang's methodological group.

Why does a comparison like this matter? Rituximab, the chimeric anti-CD20 monoclonal antibody, is established therapy for pemphigus vulgaris, an autoimmune blistering disease driven by anti-desmoglein antibodies. Ofatumumab, a fully human anti-CD20 antibody, has generated interest as an alternative — but comparative, real-world effectiveness data in pemphigus have been thin.

The supplement format carries the abstract and study design. The full cohort details — patient numbers, endpoints such as time to disease control or remission, and safety comparisons — sit in the published supplement pages rather than in the abstract record alone.

What does this change for clinicians?

For dermatologists managing pemphigus vulgaris, the practical question is whether a fully human anti-CD20 agent offers comparable or better disease control with a different safety or immunogenicity profile than rituximab. Real-world cohort evidence — as opposed to registry anecdotes — is the evidence class that typically shifts prescribing conversations before randomized trials are feasible in rare diseases.

Readers can locate the study under its supplement citation and evaluate the cohort characteristics and outcome definitions directly.

Whether ofatumumab emerges as a genuine alternative or a niche option will depend on how the full results hold up against rituximab's established benchmark in pemphigus care.